David Johnson is a Psychiatry physician. ClinicalTrials.gov lists 17 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8400 Normandale Lake Blvd Ste 920
Bloomington, MN 554373843
Telephone
952-395-7212Provider last certified this registry record 27 Jun 2025.
Clinical trials
- Assessing Uniqueness of Inflammatory Bowel Disease Related Microbiome-derived Biomarkers
Sponsor: HyGIeaCare, Inc.
- INCremental Dialysis to Improve Health Outcomes in People Starting Haemodialysis (INCH-HD)
Sponsor: The University of Queensland
- Evaluation of Stool Microbiome Using HyGIeaCare Prep
Sponsor: HyGIeaCare, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
94.7%Atypical Antipsychotic31.1%Olanzapine20%Lurasidone Hcl20%Quetiapine Fumarate15%Invega Sustenna8%Paliperidone Er7%Vraylar7%Aripiprazole7%Abilify Maintena6%Ziprasidone Hcl4%Olanzapine Odt3%Nuplazid3%Quetiapine Fumarate Er2%Part D<11 patientsBenzodiazepine11.3%Lorazepam38%Clonazepam38%Alprazolam24%Part D<11 patients+ 23 more classes in this area
Cardiovascular
4.2%alpha-Adrenergic Blocker2.3%Prazosin Hcl100%Part D<11 patientsBeta blocker1.3%Propranolol Hcl100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
1.1%Biguanide (metformin)0.6%Metformin Hcl Er100%Part D<11 patientsSerotonin-3 Receptor Antagonist0.5%Ondansetron Odt100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”